- Home
- ELDN vs CVRX Comparison
ELDN vs CVRX Comparison
Compare ELDN & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- CVRX
- Stock Information
- Founded
- ELDN 2004
- CVRX 2000
- Country
- ELDN United States
- CVRX United States
- Employees
- ELDN N/A
- CVRX N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ELDN Health Care
- CVRX Health Care
- Exchange
- ELDN Nasdaq
- CVRX Nasdaq
- Market Cap
- ELDN 178.4M
- CVRX 181.5M
- IPO Year
- ELDN N/A
- CVRX 2021
- Fundamental
- Price
- ELDN $3.06
- CVRX $6.48
- Analyst Decision
- ELDN Strong Buy
- CVRX Buy
- Analyst Count
- ELDN 1
- CVRX 7
- Target Price
- ELDN $16.00
- CVRX $14.50
- AVG Volume (30 Days)
- ELDN 214.2K
- CVRX 501.3K
- Earning Date
- ELDN 05-14-2025
- CVRX 05-08-2025
- Dividend Yield
- ELDN N/A
- CVRX N/A
- EPS Growth
- ELDN N/A
- CVRX N/A
- EPS
- ELDN N/A
- CVRX N/A
- Revenue
- ELDN N/A
- CVRX $52,870,000.00
- Revenue This Year
- ELDN N/A
- CVRX $13.92
- Revenue Next Year
- ELDN N/A
- CVRX $19.89
- P/E Ratio
- ELDN N/A
- CVRX N/A
- Revenue Growth
- ELDN N/A
- CVRX 25.62
- 52 Week Low
- ELDN $2.30
- CVRX $4.30
- 52 Week High
- ELDN $5.54
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- ELDN 49.05
- CVRX 45.14
- Support Level
- ELDN $2.96
- CVRX $6.08
- Resistance Level
- ELDN $3.27
- CVRX $7.17
- Average True Range (ATR)
- ELDN 0.17
- CVRX 0.58
- MACD
- ELDN 0.02
- CVRX 0.15
- Stochastic Oscillator
- ELDN 53.33
- CVRX 70.58
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.